Quanterix (QTRX)
(Delayed Data from NSDQ)
$15.62 USD
+0.26 (1.69%)
Updated Jun 6, 2024 04:00 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
QTRX 15.62 +0.26(1.69%)
Will QTRX be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for QTRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for QTRX
Wall Street Analysts Believe Quanterix (QTRX) Could Rally 67.66%: Here's is How to Trade
Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates
QTRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Quanterix (QTRX) AD Offering Gets FDA's Breakthrough Device Tag
Quanterix Corporation (QTRX) Reports Q4 Loss, Tops Revenue Estimates
Quanterix (QTRX) Expands in Alzheimer's Testing With Alliances
Other News for QTRX
Analysts Offer Insights on Healthcare Companies: AstraZeneca (AZN), Quanterix (QTRX) and Owlet (OWLT)
Quanterix to Present at 45th Annual Goldman Sachs Global Healthcare Conference
What's Driving Establishment Labs Holdings Inc's Surprising 19% Stock Rally?
Quanterix to Present at Leerink Partners Healthcare Crossroads Conference 2024
Outperform Rating and $30 Price Target for Quanterix Amid Strong Position in Alzheimer’s Diagnostics Market